- Active Substance: CJC 1295 DAC
- Concentration: 2 mg
- Pack Size: vial
- Manufacturer: Ultima Pharmaceuticals
- Brand Name: CJC-1295
SKU: P246
Shipping From
Understanding Ultima-CJC 1295 DAC 2mg for Growth Hormone Release Research
Ultima-CJC 1295 DAC, offered by Ultima Pharmaceuticals, contains 2mg per vial of a Growth Hormone Releasing Hormone (GHRH) peptide analog. CJC-1295 with Drug Affinity Complex (DAC) is being investigated in research settings for its potential to provide a long-lasting increase in growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels.
Mechanism of Action
CJC-1295 DAC is a synthetic peptide that mimics the action of endogenous GHRH. GHRH stimulates the pituitary gland to release growth hormone. The addition of the Drug Affinity Complex (DAC) to the CJC-1295 peptide allows it to bind to albumin in the bloodstream, significantly extending its half-life. This prolonged circulation leads to a sustained, pulsatile release of GH, which in turn promotes increased IGF-1 production by the liver.
Potential Research Benefits
- Investigated for its potential to increase growth hormone and IGF-1 levels over an extended period.
- Studied for its potential effects on muscle growth, fat loss, and overall body composition.
- Research into its possible role in improving sleep quality and promoting recovery.
- Exploration of its effects on collagen production and skin health.
Please note: The potential benefits listed above are based on preclinical and some limited clinical research and have not been fully established in humans for widespread therapeutic use. CJC-1295 DAC is not approved for human therapeutic use by regulatory authorities in many regions.
Usage Guidelines
As a research compound, any guidelines regarding its use are strictly within the context of laboratory and research settings. Administration protocols and dosages vary significantly depending on the specific research objectives and models. Common routes of administration in research include subcutaneous or intramuscular injection. Due to the DAC component, dosing is typically less frequent compared to shorter-acting GHRH analogs. Any information regarding human dosage or administration is speculative and not recommended.
Potential Side Effects (Based on Research)
Research on CJC-1295 DAC has reported some potential side effects, including injection site reactions, water retention, and transient increases in prolactin levels. The long-term safety profile and the full range of potential side effects are still under investigation.
FAQ
What is Ultima-CJC 1295 DAC?
Ultima-CJC 1295 DAC is a synthetic peptide analog of Growth Hormone Releasing Hormone (GHRH) with an added Drug Affinity Complex (DAC) to extend its duration of action.
How does CJC 1295 DAC work in research?
Research suggests it stimulates the pituitary gland to release growth hormone in a sustained manner, leading to increased GH and IGF-1 levels.
What are the potential research benefits of CJC 1295 DAC?
Potential research benefits include increased GH and IGF-1 levels, and studies into its effects on muscle growth, fat loss, sleep, and skin health.
What are the potential side effects observed in research?
Potential side effects reported in research include injection site reactions, water retention, and transient increases in prolactin.
Important Note: Ultima-CJC 1295 DAC is a research compound and is not approved for human therapeutic use by regulatory authorities in many regions. Information provided here is strictly for research and informational purposes only. It is not intended as a guide for personal use. The use of such compounds carries potential risks, and their long-term effects are not fully understood. Consult with qualified healthcare professionals for any health concerns.